Denali Therapeutics to report Q3 2026 financial results on November 3, 2026

Denali Therapeutics announced it will release its third quarter 2026 financial results and business highlights on November 3, 2026. The company will hold a conference call and webcast to discuss the results and provide a business update. Denali specializes in biotherapeutics designed to cross the blood-brain barrier, aiming to treat neurodegenerative diseases and other serious conditions. Investors can access the webcast and presentation on Denali's website, with a replay available for a limited time after the call.

As of Oct 23, 2026 03:11 WIB, Denali Therapeutics (DNLI) shares trade at USD 18.64 on Pluang, showing a slight 0.21% decline in the past day. The company holds a market capitalization of $2.99 billion and an enterprise value of $2.31 billion. This trading activity provides a current market snapshot ahead of Denali's upcoming third quarter 2026 financial results announcement on November 3, 2026.